BOULDER, CO / ACCESSWIRE / / Informa Market's New Hope Network and Nutrition Business Journal (NBJ) unveil a special report ...
Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...
Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...
The biotech said it would use the cash to “further accelerate” a portfolio led by its GLP-1 receptor agonist MET-097 ...
GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...
Poorer folks' access to blockbuster weight-loss drugs through Medicaid remains ... treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered.
GLP-1 receptor agonists, originally developed for managing type ... By reducing hunger and promoting a feeling of fullness, ...
A new Northbrook pharma will work to bring its obesity treatment to market that it says holds advantages over Ozempic and its ...
By now, stories of people achieving their weight loss goals while taking Ozempic, Zepbound, or other GLP-1 receptor agonists abound—but that doesn’t mean everyone will shed pounds on these ...